News >

Expert Highlights Advances in MCL and DLBCL

Jessica Hergert
Published: Monday, Jan 20, 2020

Charalambos (Babis) Andreadis, MD, MSCE, associate professor of clinical medicine in the Department of Medicine at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Cente

Charalambos (Babis) Andreadis, MD, MSCE

Recent data from the phase III ZUMA-2 trial demonstrated an unprecedented 93% objective response rate in patients with relapsed/refractory mantle cell lymphoma (MCL) who received a single infusion of the investigational CAR T-cell therapy KTE-X19, said Charalambos (Babis) Andreadis, MD, MSCE.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication